Innovative App Determines Prostate Cancer Risk Level

          App for individualized prostate cancer prevention opens up new possibilities

          The ProstateCheck app promotes early detection of the dangerous disease and helps to prevent unnecessary screenings by extending previous check-up intervals of one year for 75% of men by up to seven years. It creates a risk analysis within seconds and therefore allows general practitioners, specialists and private individuals to get a quick, reliable analysis. 

          "The ProstateCheck app is intended to remind men of their prostate cancer screening early on", explains Prof. Dr. Franz Recker, Chairman of the Swiss Prostate Cancer Research Foundation and Head of Urology at the Aarau Cantonal Hospital. "At the same time, it is important that we don't screen everybody annually but instead focus on those who are at risk." ProstateCheck, which was co-developed by Dr. Recker and his colleague Dr. Maciej Kwiatkowski, prevents unnecessary examinations, for not every tumor that is detected early on needs to be treated. Between 30% and 40% of men will have tumor cells in their prostate at some point that do not require treatment. However, every day 6,000 men worldwide develop a malignant tumor in their prostate. Often it is detected in a later stage, which causes success rates for treatment to sink drastically.

          The app is based on the most comprehensive long-term study of prostate cancer screenings in the German-speaking region and calculates the likelihood of prostate cancer based on the user's individual, medical data that he receives during an ordinary check-up. Alongside required information such as the PSA level and the user's age, information about any family history of prostate cancer, the results of the palpation, and the volume of the prostate increase the precision of the ProstateCheck prognosis. Based on the user's information, the app uses specially developed algorithms to calculate the probability of a malignant tumor. Besides, the probability of the user developing prostate cancer in the next four, eight and twelve years is calculated. The app can extend the amount of time between screenings by up to seven years. The resulting reduction in the frequency of prostate examinations will serve to increase the efficiency of medical screening processes, reduce unnecessary diagnoses, and greatly reduce the cost burden on the health-care system.

          The ProstateCheck app is available for download from 2 Euros in the Apple App Store and the Google Play Store for Android devices. The app is available in English, German, Hindi, Chinese, Arabic and Spanish. For journalists the app comes along with a Free Code. To test the app, please insert following Username and Password under "Code":

          User: stiftung_presse

          Password: 8vga5jxj

          Explanation video: http://youtu.be/dnUXrlG-Eyk

          Download-Links:

          https://itunes.apple.com/ch/app/prostatecheck/id940032317?mt=8&uo=4

          https://play.google.com/store/apps/details?id=ch.prostatakrebs.ProstateCheck

          Press Office

          Christoph Kinsperger
          +41-(0)43-254-66-22
          [email protected]
          http://www.prostatakrebs.ch

          Source: Prostate Cancer Research Foundation Switzerland
 


ข่าวProstate Cancer+o:healวันนี้

UK - National Institute for Health and Care Excellence (NICE) Issues MedTech Innovation Briefing on 'Trublood(R)- Prostate' for Precision Non-invasive Prostate Cancer Diagnosis Described by Experts as a 'Game Changer'

Datar Cancer Genetics, a world leading non-invasive cancer analytics and diagnostics company having its Research Head Quarters at Nasik, India, announced the publication of the internationally recognized MedTech Innovation Briefing (MIB) from the United Kingdom's National Institute for Health and Care Excellence (NICE) on its CE marked 'Trublood(R)- Prostate' test to be used for precision triaging of patients to avoid unnecessary invasive biopsies. MIBs are published as "NICE advice" series to U

MIM Software Inc. ประกาศความร่วมมือกับ Peter MacCallum Cancer Centre เพื่อปรับปรุงการจัดการผู้ป่วย

MIM Software Inc. บริษัทชั้นนำระดับโลกผู้ให้บริการซอฟต์แวร์การถ่ายภาพทางการแพทย์ ประกาศความร่วมมือกับโรงพยาบาล Peter MacCallum Cancer Centre (Peter Mac) ผ่านทางโปรแกรม Prostate Cancer Theranostics and...

MIM Software Inc. Announces Collaboration with Peter MacCallum Cancer Centre to Improve Patient Management

MIM Software Inc., a leading global provider of medical imaging software, announced today a collaboration with Peter MacCallum Cancer Centre (Peter Mac) in support of its Prostate Cancer...

miR Scientific Announces Validation of its Urine Based, Non-Invasive Prostate Cancer Test Published in the Journal of Urology

- Validated Data Reinforces Capability to Molecularly Detect and Characterize Prostate Cancer with Concurrent Sensitivity and Specificity of Over 91% - Data Support...

นพ.พงษ์สันติ์ ลี้สัมพันธ์ (ขวา) รองผู้อำน... ภาพข่าว: โครงการความร่วมมือระหว่าง รพ.รามาธิบดี และรพ.หัวเฉียว — นพ.พงษ์สันติ์ ลี้สัมพันธ์ (ขวา) รองผู้อำนวยการฝ่ายคุณภาพ โรงพยาบาลหัวเฉียว ร่วมถ่ายภาพกับ...

Innovative App Determines Prostate Cancer Risk Level

App for individualized prostate cancer prevention opens up new possibilities The ProstateCheck app promotes early detection of the dangerous disease and helps to prevent unnecessary screenings by extending previous check-up intervals of one year...

23 Patients With Organ Confined Low Risk Prostate Cancer Have Been Treated in Clinical Trials Using the ExAblate(R) Non-Invasive Prostate Cancer System

Initial Results are Encouraging, Spurring Hope for a Treatment Option with a Lower Rate of Complications InSightec Ltd., the global leader in MR...

InSightec Treats First Prostate Cancer Patients in Clinical Trials

- ExAblate(R) MR Guided Focused Ultrasound System is Being Used for the First Time for Non-invasive Treatment of Prostate Cancer - Seven Patients With Prostate Confined Low Risk Cancer Treated in Clinical Trials InSightec Ltd., the...

Committee for Medicinal Products for Human Use (CHMP) Recommends Granting Marketing Authorisation for FIRMAGON(R) (degarelix) for Treatment of Prostate Cancer

- New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-Term Suppression of Testosterone Ferring...